Phathom Pharmaceuticals, Inc. PHAT Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s other commercial liabilities?
- Phathom Pharmaceuticals, Inc. (PHAT) reported other commercial liabilities of $83.32M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s other commercial liabilities changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s other commercial liabilities increased by 93.6% year-over-year, from $43.03M to $83.32M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s other commercial liabilities has grown at a 53.3% compound annual growth rate (CAGR), from $10.61M to $89.83M.